Keraplast Technologies, a biotech company specializing in the extraction and processing of keratin from New Zealand wool, is on the cusp of expanding its product offerings into the nutraceuticals and pharmaceuticals markets. Chief Executive Howard Moore recently highlighted the potential health benefits of keratin, including its ability to minimize osteoporosis, promote gut health, and serve as an anti-inflammatory agent. This comes on the heels of promising research from Otago University, which indicates that keratin may also help reduce insulin resistance.
During a recent visit to Keraplast’s new facility in Christchurch, Prime Minister Christopher Luxon was introduced to the innovative processes that transform wool into unique, branded ingredients primarily exported for beauty and personal care products. Moore emphasized the company’s commitment to scientific research and development, noting that Keraplast has been at the forefront of keratin technology for over 25 years. The partnership between Keraplast and Keratec, a company that originated from the New Zealand Wool Board, has created a synergy that Moore describes as a “marriage made in heaven,” despite Keraplast now being fully owned by an American entity.
The keratin market is estimated at around $2 billion globally, with much of the competition coming from commodity products sourced from chicken feathers in countries like Brazil, China, and Mexico. Keraplast distinguishes itself by utilizing wool, which is not only a sustainable resource—sourced exclusively from regeneratively farmed New Zealand sheep—but also offers added value through its innovative applications. Last year, the company processed 77 tonnes of wool, and with its new facility, it aims to increase this capacity to 300 tonnes annually.
Prime Minister Luxon praised Keraplast’s achievements, noting the importance of enhancing the value derived from New Zealand’s wool industry. He acknowledged that wool has faced challenges in innovation over the past three decades, but highlighted Keraplast’s efforts as a positive story that could reshape perceptions of the sector. Luxon also pointed out the need for improved collaboration in research and development among universities, businesses, and research institutions to foster innovation.
As Keraplast looks to broaden its horizons, the implications of its work extend beyond economic benefits. By focusing on sustainable practices and harnessing the potential of keratin, the company is not only contributing to New Zealand’s manufacturing landscape but also addressing global health concerns. This shift towards nutraceuticals and pharmaceuticals could position Keraplast as a leader in a burgeoning market, showcasing the versatility and value of New Zealand wool in ways that resonate with both consumers and health-conscious markets.
